GRAND RAPIDS, Mich.– Corium Pharma Solutions, Inc. (“Corium Pharma Solutions” or “CPSI”), a leading, full-service contract development and manufacturing organization specializing in novel drug delivery technologies, including transdermal modalities, today announced the appointment of Dr. Mark Sirgo as Chief Executive Officer and member of the Board of Directors. Dr. Sirgo is a pharmaceutical executive with over 35 years’ experience in the industry, including founding and serving as the President, Chief Executive Officer, and Vice Chairman of BioDelivery Sciences International, Inc. (“BDSI”), a commercial-stage specialty pharmaceutical company focused on pain and addiction management.
During his tenure at BDSI, Mark was responsible for creating and overseeing the implementation of the company’s corporate strategy and overseeing all business operations. Additionally, Mark executed on the development, NDA approval, and commercialization of three products in neurological and pain indications, Onsolis®, Bunavail®, and Belbuca®. BDSI was successfully sold to Collegium Pharmaceutical, Inc. in March 2022.
Founded in 1995 in Grand Rapids, Michigan, Corium Pharma Solutions has maintained longstanding partnerships with multinational Fortune 500 companies and pharmaceutical businesses alike. CPSI currently manufactures a variety of over the counter and prescription products, including Proctor & Gamble Co’s (NYSE: PG) entire Crest Whitestrips franchise, Agile Therapeutics, Inc.’s (NASDAQ: AGRX) Twirla®, and Corium, LLC’s (“Corium”) ADLARITY®, a once-weekly, transdermal donepezil patch indicated for the treatment of mild, moderate, and severe dementia in Alzheimer’s patients.
Mark joins Corium Pharma Solutions shortly after its formation in October 2022, when Webster Equity Partners (“Webster”) acquired the standalone business unit from its former, commercial-stage biopharmaceutical parent company, Corium. Corium’s original investor, Gurnet Point Capital (“Gurnet Point”), remains as a joint owner in Corium Pharma Solutions and each Gurnet Point and Webster have equal board representation.
“I am thrilled to welcome Mark as Chief Executive Officer of Corium Pharma Solutions,” said Travis Wilson, Partner at Gurnet Point. “Mark’s decades of industry experience and proven track record of research, development, and commercialization of pharmaceutical products make him the ideal leader for the next phase of Corium Pharma Solutions’ growth. He is uniquely qualified to step into the leadership role and Corium Pharma Solutions will benefit from his deep product development, regulatory, and commercial experience across numerous therapeutics areas.”
“I am excited to have the opportunity to lead the Corium Pharma Solutions team as we continue to build on the company’s historical successes and further establish its leadership position in transdermal contract development and manufacturing,” said Dr. Mark Sirgo, Chief Executive Officer. “With the backing and financial support of Gurnet Point and Webster, I look forward to focusing on both supporting our current partners and procuring new business opportunities within our current capabilities, while selectively adding to our breadth of specialty offerings through M&A to extend our commercial product footprint.”
Prior to founding BDSI, Mark was Senior Vice President, Global Business Development at PPD, Inc., where he managed global sales and marketing for one of the world’s largest contract research organizations serving biopharmaceutical, pharmaceutical, and device industries. Further, he held several leadership positions at GSK plc in clinical development and marketing and was a Director at Salix Pharmaceuticals, Ltd. prior to its sale to Valeant Pharmaceuticals International, Inc. in 2015. Mark also currently serves as Chairman of 9 Meters Biopharma, Inc. (NASDAQ: NMTR) and Genenta Science SpA (NASDAQ: GNTA).
Dr. Sirgo holds a PharmD from Philadelphia College of Pharmacy and Sciences, and a BS in Pharmacy from The Ohio State University.
